Purpose: This study aimed to assess the efficacy of high-dose i.v. immunoglobulin (HIVIg) therapy in pregnant women with antiphospholipid syndrome (APS) secondary to systemic lupus erythematosus with a history of pregnancy failure, despite receiving low-dose aspirin plus unfractionated heparin therapy, of which condition being designated as "aspirin-heparin-resistant APS" (AHRAPS).
used as a standard therapeutic modality worldwide. However, 20%-30% of pregnancies in women with APS who have a history of RM result in fetal loss again, despite receiving LDA plus heparin therapy. 6 Such cases have been designated as aspirin-heparin-resistant antiphospholipid syndrome (AHRAPS). 7 Some case reports have shown that high-dose i.v. immunoglobulin (HIVIg) therapy leads to a live birth for pregnant women with AHRAPS successfully. [7] [8] [9] The present study reports on the experience of HIVIg therapy in eight pregnancies from five women with AHRAPS.
| MATERIALS AND METHODS
This prospective study was approved by the institutional ethical Gradipore, Ltd., Frenchs Forest, NSW, Australia) was used for the LA measurements. A screen clotting time/confirm clotting time ratio of 1.3 was defined as the cut off value of LA. The IgG, IgM, and aCL were measured by using an enzyme-linked immunosorbent assay (MESACUP cardiolipin test IgG/IgM; MBL Company, Ltd., Nagoya, Japan), based on the methods described in one of the studies: 11 10 U/mL of IgG and 8 U/mL of IgM were defined as the cut-off values. The IgG aCLβ2GPI
was measured by using an enzyme immunoassay (Anti-CLβ2GPI
Yamasa EIA Kit; Yamasa Company, Ltd., Tokyo, Japan): 3.5 U/mL was defined as the cut off value. In the present study, IgG aCLß2GPI was measured for IgG aβ2GPI. The IgM aCLβ2GPI measurement is not commercially available in Japan. The IgG anti-phosphatidylserine/prothrombin antibody (aPS/PT) was measured by using an enzyme-linked immunosorbent assay (aPS/PT ELISA Kit; MBL Company, Ltd.): 12 U/ mL was defined as the cut-off value.
The pregnant women received HIVIg therapy (intact-type immunoglobulin 20 g daily over a course of 5 days; a total dose of 100 g) in addition to LDA plus heparin therapy. The HIVIg therapy was commenced after a gestational sac in the uterus was detected by transvaginal ultrasound at an earlier gestational age than that at which previous fetal losses had occurred. 
| RESULTS
The HIVIg therapy was given for eight pregnancies for five women with AHRAPS. Table 1 shows the clinical backgrounds and outcomes of these eight pregnancies, which were complicated by systemic lupus erythematosus (SLE). SLE was controlled at conception in the index pregnancy, as well as previous pregnancies. Seven of the eight pregnancies had no hypocomplementemia at conception, while one (case 4) had mild hypocomplementemia (CH50: 18.2 U/mL; C3: 53 mg/dL; C4: 7.3 mg/dL). A SLE flare during pregnancy was observed in only one case (case 1-2).
Three of the eight pregnancies ended in miscarriages (cases 1-1, T A B L E 1 Continued activity was found using Wilcoxon's matched pairs test. However, the NK cell activity was suppressed by HIVIg in case 2 and 3, who had
higher levels of NK cell activity before HIVIg, while the NK cell activity did not change after HIVIg in cases 1 and 5, who had lower levels of NK cell activity before HIVIg.
| DISCUSSION
Randomized controlled studies have shown that LDA plus heparin therapy is effective in improving the live birth rate 4,5 and reducing morbidity 12, 13 in pregnant women with APS who have a history of RM.
Although LDA plus heparin is recommended as a standard therapy, 4 high rates of low birthweight newborns, 14 FGR, and premature delivery 15 are observed in pregnant women with APS and LDA plus heparin therapy. Unfortunately, 20%-30% of pregnancies in women with APS who have a history of RM result in fetal loss again, despite receiving LDA plus heparin therapy. 6 Such cases are designated as AHRAPS.
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In the present study, HIVIg therapy was successful in four (57.1%) of the seven pregnancies, yielding a live birth rate of 71.4% (5/7) in the women with AHRAPS. These relatively high rates of success and live births using HIVIg therapy imply the possible efficacy of this therapeutic modality for pregnant women with AHRAPS, which is the most severe manifestation of APS. Obstetrical complications, such as premature delivery, FGR, HDP, NRFS, and oligohydramnios, were observed frequently in this study. Therefore, careful perinatal management is necessary during pregnancies in women with AHRAPS who receive HIVIg therapy.
High-dose i.v. immunoglobulin therapy is known to be practically effective and this therapeutic modality has long been applied to a wide variety of immune-mediated diseases, including idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, Kawasaki's disease, and myasthenia gravis. 16, 17 The HIVIg therapy (20 g/d, five consecutive days, total 100 g) for the women who had a history of four or more consecutive spontaneous abortions of unexplained etiology has been developed by the authors' group, yielding an 89.8%
live birth rate. 18 One study first reported successful HIVIg therapy 
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Therefore, HIVIg therapy might serve as an effective immune modifier in pregnant women with a pathophysiology underlying AHRAPS.
However, the precise indication of women with AHRAPS who should receive HIVIg therapy remains unknown. Similar to previous reports of IVIg therapy in women with RM, 23 the suppression of NK cell activity in pregnant women who had higher levels of NK cell activity before HIVIg was observed in this study. But, it is unclear whether the suppression of NK cell activity is associated with a better pregnancy outcome in women with AHRAPS.
The medical cost of HIVIg is much higher than that of LDA plus heparin therapy. The results of the present study included several uncertainties. The enrollment of the participants in the study design was not randomized nor placebo-controlled. In order to prove the efficacy of HIVIg therapy in pregnant women with AHRAPS and a history of RM, a randomized placebo-controlled study is necessary in the future.
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